A decade of investment in infection prevention: A cost-effectiveness analysis

American Journal of Infection Control

Volumn 43, Issue 1, 2015, Pages 4-9

  Dick, Andrew W ^a   Perencevich, Eli N ^b   Pogorzelska Maziarz, Monika ^c   Zwanziger, Jack ^d   Larson, Elaine L ^e,f   Stone, Patricia W ^f  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Department of Medicine   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Central lineeassociated bloodstream infections; Cost analysis; Economic evaluation; Long term costs; Quality of life; Ventilator associated pneumonia

Indexed keywords

AGED; ARTICLE; CATHETER INFECTION; CHRONIC PATIENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INFECTION PREVENTION; INTENSIVE CARE UNIT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; QUALITY ADJUSTED LIFE YEAR; VENTILATOR ASSOCIATED PNEUMONIA; COHORT ANALYSIS; COST BENEFIT ANALYSIS; CROSS INFECTION; ECONOMICS; INFECTION CONTROL; PROCEDURES;

AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; CROSS INFECTION; FEMALE; HUMANS; INFECTION CONTROL; MALE;

EID: 84927554558     PISSN: 01966553     EISSN: 15273296     Source Type: Journal    
DOI: 10.1016/j.ajic.2014.07.014     Document Type: Article

References (31)

1. Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA, et al. Estimating health careeassociated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007;122: 160-6.
2. Scott R. The direct medical costs of health careeassociated infections in U.S. hospitals and the benefits of prevention. Available from: Http://www.cdc.gov/HAI/pdfs/hai/Scott-CostPaper.pdf. Accessed November 21, 2013.
3. Eber MR, Laxminarayan R, Perencevich EN, Malani A. Clinical and economic outcomes attributable to health careeassociated sepsis and pneumonia. Arch Intern Med 2010;170: 347-53.
4. Dudeck MA, Horan TC, Peterson KD, Allen-Bridson K, Morrell G, Pollock DA, et al. National Healthcare Safety Network (NHSN) report, data summary for 2010, device-Associated module. Am J Infect Control 2011;39: 798-816.
5. Yokoe DS, Mermel LA, Anderson DJ, Arias KM, Burstin H, Calfee DP, et al. A compendium of strategies to prevent healthcare-Associated infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29: S12-21.
6. Berwick DM, Calkins DR, McCannon CJ, Hackbarth AD. The 100, 000 lives campaign: Setting a goal and a deadline for improving health care quality. JAMA 2006;295: 324-7.
7. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355: 2725-32.
8. Furuya EY, Dick A, Perencevich EN, Pogorzelska M, Goldmann D, Stone PW. Central line bundle implementation in US intensive care units and impact on bloodstream infections. PLoS One 2011;6: E15452.
9. Pogorzelska M, Stone PW, Furuya EY, Perencevich EN, Larson EL, Goldmann D, et al. Impact of the ventilator bundle on ventilator-Associated pneumonia in intensive care unit. Int J Qual Health Care 2011;23: 538-44.
10. Kim JS, Holtom P, Vigen C. Reduction of catheter-related bloodstream infections through the use of a central venous line bundle: Epidemiologic and economic consequences. Am J Infect Control 2011;39: 640-6.
11. Scales DC, Dainty K, Hales B, Pinto R, Fowler RA, Adhikari NK, et al. A multifaceted intervention for quality improvement in a network of intensive care units: A cluster randomized trial. JAMA 2011;305: 363-72.
12. US Department of Health and Human Services. National action plan to prevent healthcare-Associated infections: National targets and metrics. Available from: Http://www.hhs.gov/ash/initiatives/hai/nationaltargets/index.html. Accessed September 9, 2013.
13. Dick A, Liu H, Zwanziger J, Perencevich EN, Furuya EY, Larson EL, et al. Longterm survival and healthcare utilization outcomes attributable to sepsis and pneumonia. BMC Health Serv Res 2012;12: 432.
14. Stone PW, Pogorzelska-Maziarz M, Herzig CT, Wiener LM, Furuya EY, Dick A, et al. State of infection prevention in US hospitals enrolled in the National Health and Safety Network. Am J Infect Control 2014;42: 94-9.
15. Centers for Disease Control and Prevention. United States life tables. Available from: Http://www.cdc.gov/nchs/products/life-Tables.htm#life. Accessed September 10, 2013.
16. Walters HR, Korn R Jr, Colantuoni E, Berenholtz SM, Goeschel CA, Needham DM, et al. The business case for quality: Economic analysis of the Michigan Keystone Patient Safety Program in ICUs. Am J Med Qual 2011;26: 333-9.
17. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32: 470-85.
18. Dudeck MA, Horan TC, Peterson KD, Allen-Bridson K, Morrell G, Antilla A, et al. National Healthcare Safety Network report, data summary for 2011, deviceassociated module. Am J Infect Control 2013;41: 286-300.
19. Reduction in central line-Associated bloodstream infections among patients in intensive care unitsdPennsylvania, April 2001eMarch 2005. MMWR Morb Mortal Wkly Rep 2005;54: 1013-6.
20. Ash AS, Posner MA, Speckman J, Franco S, Yacht AC, Bramwell L. Using claims data to examine mortality trends following hospitalization for heart attack in Medicare. Health Serv Res 2003;38: 1253-62.
21. Ellis RP, Ash A. Refinements to the diagnostic cost group (DCG) model. Inquiry 1995;32: 418-29.
22. Petersen LA, Pietz K, Woodard LD, Byrne M. Comparison of the predictive validity of diagnosis-based risk adjusters for clinical outcomes. Med Care 2005; 43: 61-7.
23. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. Cost-effectiveness analysis registry. Available from: Https://research.tuftsnemc. org/cear4. Accessed September 10, 2013.
24. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectivenss in Health and Medicine. JAMA 1996;276: 1253-8.
25. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)e explanation and elaboration: A report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16: 231-50.
26. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 1999;282: 554-60.
27. Halton KA, Cook D, Paterson DL, Safdar N, Graves N. Cost-effectiveness of a central venous catheter care bundle. PLoS One 2010;5: E12815.
28. Keller SC, Linkin DR, Fishman NO, Lautenbach E. Variations in identification of healthcare-Associated infections. Infect Control Hosp Epidemiol 2013;34: 678-86.
29. Chambers JD, Neumann PJ, Buxton MJ. Does medicare have an implicit costeffectiveness threshold? Med Decis Making 2010;30: E14-27.
30. Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: A German perspective. Cost Eff Resour Alloc 2009;7: 9.
31. Wagner M, Lindgren P, Merikle E, Goetghebeur M, Jonsson B. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial. Can J Cardiol 2009;25: E362-9.